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Objectives: To compare the long term prognosis of patients having silent versus symptomatic ischaemia
during dobutamine stress echocardiography (DSE).
Design: Observational study.
Setting: Tertiary referral centre.
Patients: 931 patients who experienced stress induced myocardial ischaemia during DSE.
Results: Silent ischaemia was present in 643 of 931 patients (69%). The number of dysfunctional segments
at rest (mean (SD) 9.6 (5.1) v 8.8 (5.0), p = 0.1) and of ischaemic segments (3.5 (2.2) v 3.8 (2.1),
p = 0.2) was comparable in both groups. During a mean (SD) follow up of 5.5 (3.3) years, there were
169 (18%) cardiac deaths and 86 (9%) non-fatal infarctions. Multivariable Cox regression analysis
showed age (hazard ratio (HR) 1.1, 95% confidence interval (CI) 1.02 to 1.05), previous myocardial
infarction (HR 1.4, 95% CI 1.1 to 2.0), and number of ischaemic segments during the test (HR 2.0, 95% CI
1.0 to 3.7) as independent predictors of cardiac death and myocardial infarction. For every additional
ischaemic segment there was a twofold increment in risk of late cardiac events. The annual cardiac death
or myocardial infarction rate was 3.0% in patients with symptomatic ischaemia and 4.6% in patients with
silent ischaemia (p , 0.01). Silent induced ischaemia was an independent predictor of cardiac death and
myocardial infarction (HR 1.7, 95% CI 1.1 to 2.0). During follow up symptomatic patients were treated
more often with cardioprotective therapy (p , 0.01) and coronary revascularisation (145 of 288 (50%) v
174 of 643 (27%), p , 0.001).
Conclusions: Patients with silent ischaemia had a similar extent of myocardial ischaemia during DSE
compared to patients with symptomatic ischaemia but received less cardioprotective treatment and
coronary revascularisation and experienced a higher cardiac event rate.
A
lthough angina pectoris is one of the cardinal
manifestations of myocardial ischaemia, many patients
have ischaemia during stress testing without asso-
ciated symptoms.1–3 Studies of stress induced silent ischaemia
reported discordant results with respect to the extent of
ischaemia. Some studies reported a similar extent of
ischaemia in patients with and without angina,4–10 whereas
others reported more extensive ischaemia in the presence of
angina.11–16 Dobutamine–atropine stress echocardiography
(DSE) is commonly used to assess the extent, location, and
severity of coronary artery disease.17 18 The diagnosis of
myocardial ischaemia during DSE is based on the detection
of new or worsening wall motion abnormalities. The extent
of these abnormalities is a powerful predictor of adverse
outcome.19 20 A large number of studies have reported
discordant data regarding the prognostic importance of stress
induced silent ischaemia, the likelihood of future coronary
events related to the amount of ischaemic myocardium, and
the influence of medical treatment or revascularisation
techniques on the outcome of silent stress induced ischaemia.
Accordingly, the objective of this study was to compare the
long term prognosis of silent versus symptomatic ischaemia
in a large group of patients undergoing DSE.
PATIENTS AND METHODS
Patient selection
Between 1990 and 2002, 949 consecutive patients experi-
enced stress induced myocardial ischaemia during DSE.
Follow up was successful in 944 patients (99.5%). Thirteen
patients underwent early coronary revascularisation in the
first 60 days after DSE and were excluded from the analysis.21
Data from the remaining 931 patients are reported. The
protocol was approved by the hospital ethics committee. All
patients gave informed consent before the test. A structured
interview and clinical history were taken and cardiac risk
factors were assessed before DSE.
Dobutamine stress protocol
Dobutamine–atropine stress testing was performed according
to a standard protocol as previously reported.19 22 23
Dobutamine was administered intravenously, starting at a
dose of 5 mg/kg/min for five minutes, followed by 10 mg/kg/
min for five minutes. Subsequently, incremental dobutamine
doses of 10 mg/kg/min were given at three minute intervals
up to a maximum dose of 40 mg/kg/min. If the test end point
was not reached at a dobutamine dose of 40 mg/kg/min,
atropine (up to 2 mg) was given intravenously. Blood
pressure, heart rate, and ECG were constantly monitored.
Test end points were achievement of the target heart rate
(85% of maximum age and sex predicted heart rate),
maximum dose of dobutamine and atropine, horizontal or
downsloping ST segment depression . 2 mm at an interval
of 80 ms after the J point compared with baseline, severe
angina, systolic blood pressure fall . 40 mm Hg, blood
pressure . 240/120 mm Hg, or significant cardiac arrhyth-
mia. An intravenous b blocker was available to reverse the
adverse effects of dobutamine and atropine.
Stress echocardiography
Two dimensional echocardiographic images were acquired at
rest, during dobutamine stress, and during recovery. The
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echocardiograms were recorded in a quad screen format. Two
experienced observers, unaware of the clinical data, scored
the echocardiograms according to a standard 16 segment
model. Regional wall motion and systolic wall thickening
were scored on a five point scale (1 indicating normal; 2, mild
hypokinesia; 3, severe hypokinesia; 4, akinesia; and 5,
dyskinesia). Ischaemia was defined as new or worsened wall
motion abnormalities during stress indicated by an increase
of wall motion score > 1 grade in > 1 segments. Ischaemia
was not considered to be present when akinetic segments at
rest became dyskinetic during stress. Symptomatic ischaemia
was defined as the presence of typical chest pain or anginal
equivalent symptoms (epigastric pain, jaw pain, and dys-
pnoea) during DSE. Coronary arteries were assigned to
myocardial segments based on echocardiographic localisa-
tion, as previously described.24 The anterior, apical, septal,
and anteroseptal walls were assigned to the left anterior
descending coronary artery, the posterior and lateral wall to
the left circumflex, and the inferior and basal septal segments
to the right coronary artery. The apical lateral segment was
considered to be an overlapping segment between the left
anterior descending coronary artery and the left circumflex,
and the apical inferior segment was considered to be an
overlapping segment between the left anterior descending
coronary artery and the right coronary artery. Overlapping
segments were assigned to the regions with concomitant
abnormalities.
Follow up
Follow up data were collected by contacting the patient’s
general practitioner and by review of hospital records. The
date of the last review or consultation was used to calculate
follow up time. Outcome events were overall death, cardiac
death, and non-fatal myocardial infarction. Cardiac death
was defined as death caused by acute myocardial infarction,
significant cardiac arrhythmias, or refractory congestive heart
failure. Sudden death occurring without another explanation
was regarded as cardiac death. Non-fatal myocardial infarc-
tion was defined by two of the following symptoms: typical
chest pain, increased cardiac enzyme concentrations, and
typical changes on ECG.
Statistical analysis
Continuous data were expressed as mean (SD). Student’s t
test was used to analyse continuous data. Differences
between proportions were compared with the x2 test.
Univariate and multivariate Cox proportional hazard regres-
sion models (BMDP Statistical Software Inc, Los Angeles,
California, USA) were used to identify independent pre-
dictors of late cardiac events.25 Variables were selected in a
stepwise forward selection manner, including clinical and
DSE data, with entry and retention set at a significance level
of 0.05. The risk of a variable was expressed as a hazard ratio
(HR) with a corresponding 95% confidence interval (CI). The
probability of survival was calculated by the Kaplan-Meier
method and survival curves were compared by the log rank
test. A probability value of p , 0.05 was considered
significant.
RESULTS
Patient characteristics and haemodynamic results
Silent myocardial ischaemia was present in 643 of 931 (69%)
patients. Clinical risk factors were not significantly different
between patients with and patients without angina during
DSE, with the exception of history of angina, which was
more often observed in patients with symptomatic ischaemia
(table 1). Table 2 shows DSE characteristics of patients with
silent and symptomatic myocardial ischaemia. There was no
significant difference between patients with and patients
without silent ischaemia with respect to the number of
abnormal segments at rest and the number of ischaemic
segments during DSE. No patient experienced a myocardial
infarction during the test. Side effects among the 931
patients were non-sustained ventricular tachycardia (, 10
complexes) in 28 (3%), sustained ventricular tachycardia
(. 10 complexes) in 13 (1%), severe hypotension (decrease
in systolic blood pressure . 40 mm Hg compared with
baseline) in seven (1%), atrial fibrillation in six (1%), and
ventricular fibrillation in one (0.1%).
DSE and outcome
During a mean (SD) 5.5 (3.3) years follow up of the 931
patients, there were 265 (28%) deaths, of which 169 (18%)
were attributed to cardiac causes. Non-fatal infarction
Table 1 Clinical characteristics of patients with and without angina during dobutamine
stress echocardiography (DSE)
Silent
ischaemia
(n = 643)
Symptomatic
ischaemia
(n = 288) p Value
Age (years)* 61 (13) 61 (11) 0.6
Men 465 (72%) 233 (81%) 0.009
Previous infarction 330 (51%) 161 (56%) 0.2
Diabetes mellitus 78 (12%) 29 (10%) 0.4
Hypertension 195 (30%) 79 (27%) 0.4
Hypercholesterolaemia 163 (25%) 82 (28%) 0.3
Smoking 122 (19%) 88 (30%) 0.3
History of angina 200 (31%) 196 (68%) ,0.001
History of heart failure 107 (17%) 38 (13%) 0.2
Previous coronary angiography 219 (34%) 112 (39%) 0.2
Previous coronary bypass surgery 96 (15%) 43 (15%) 1
Previous coronary angioplasty 89 (14%) 56 (19%) 0.04
b Blockers 243 (38%) 115 (40%) 0.5
Calcium channel blockers 177 (27%) 99 (34%) 0.04
Nitrates 180 (28%) 115 (40%) 0.001
Aspirin 302 (47%) 158 (55%) 0.005
Statins 174 (27%) 92 (32%) 0.01
Indication for DSE
Diagnosis of CAD 350 (54%) 211 (73%) ,0.0001
Preoperative evaluation before non-cardiac surgery 186 (29%) 34 (12%) ,0.0001
Risk stratification after MI 107 (17%) 43 (15%) 0.6
*Mean (SD).
CAD, coronary artery disease; MI, myocardial infarction.
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occurred in 86 (9%) patients and late revascularisation was
performed in 319 (34%) patients. The annual cardiac death
rate was 2.2% in the group of patients with symptomatic
ischaemia during DSE and 3.8% in the group with silent
ischaemia (p , 0.01). The annual myocardial infarction or
cardiac death rate was 3.0% in patients with symptomatic
ischaemia and 4.6% in patients with silent ischaemia
(p , 0.01). Late revascularisation was more often performed
in patients with symptomatic ischaemia (145 of 288 (50%) v
174 of 643 (27%), p , 0.001). Medical treatment was
changed after detection of ischaemia by DSE in both groups
but patients with angina during DSE were significantly more
often treated with b blockers, aspirin, and statins (table 3).
On the other hand, the fact that fewer of these patients were
treated with nitrates and calcium channel blockers at follow
up is related to the higher incidence of coronary revascular-
isation in this group.
Figures 1 and 2 present Kaplan-Meier survival curves for
the end point cardiac death and the combined end point
cardiac death or non-fatal infarction, respectively. Patients
with silent ischaemia had a significantly lower probability of
survival during long term follow up than patients with
symptomatic ischaemia. In particular, patients with silent
ischaemia and multivessel disease had a poor long term
prognosis (fig 3). This may be related to the fact that patients
with symptomatic ischaemia and multivessel disease were
more often referred for coronary revascularisation than
patients with silent ischaemia and multivessel disease (111
of 220 (50%) v 141 of 509 (28%), p , 0.0001). Among
patients with symptomatic ischaemia and multivessel dis-
ease, cardiac death occurred in 11 of 111 (11%) patients who
were revascularised versus 22 of 109 (20%) patients who
were treated medically (p = 0.05). Similarly, in patients
with silent ischaemia and multivessel disease, cardiac death
occurred in 18 of 141 (13%) patients who were revascularised
versus 92 of 368 (25%) medically treated patients
(p = 0.004).
No sex differences for cardiac death or hard cardiac events
were present in the overall population, in the two groups of
patients with symptomatic or silent ischaemia, or in the two
groups of patients with single or multivessel disease.
Incremental prognostic value
Independent predictors of cardiac death in a multivariate
analysis were age (HR 1.1, 95% CI 1.04 to 1.08), male sex (HR
1.8, 95% CI 1.2 to 2.7), smoking (HR 1.5, 95% CI 1.1 to 2.0),
and the number of ischaemic segments during DSE (HR 2.1,
95% CI 1.1 to 4.1). Independent predictors of cardiac death or
myocardial infarction were age (HR 1.1, 95% CI 1.02 to 1.05),
previous myocardial infarction (HR 1.4, 95% CI 1.1 to 2.0),
and the number of ischaemic segments during DSE (HR 2.0,
95% CI 1.0 to 3.7). For every ischaemic segment there was a
twofold increment in risk of late cardiac events. Silent
induced ischaemia was also an independent predictor of
cardiac death and myocardial infarction (HR 1.7, 95% CI 1.1
to 2.0). An interaction term between silent induced ischae-
mia and the presence of ischaemia was not significant.
DISCUSSION
The current results show that patients with silent myocardial
ischaemia during DSE have a higher incidence of long term
cardiac death and myocardial infarction than do patients
with symptomatic myocardial ischaemia. This association
was observed irrespective of the presence and extent of
resting or dobutamine stress induced new wall motion
abnormalities.
Table 2 DSE data for patients with and without angina during DSE
Silent ischaemia
(n = 643)
Symptomatic
ischaemia (n = 288) p Value
Peak heart rate (beats/min) 127 (21) 124 (20) 0.03
Peak systolic blood pressure (mm Hg) 135 (31) 134 (28) 0.7
Peak rate pressure product 16 573 (4290) 17 119 (4767) 0.1
Peak dobutamine dose (mg) 37 (7) 38 (5) 0.09
Atropine use 230 (36%) 96 (33%) 0.5
ST segment depression 248 (38%) 179 (62%) ,0.001
Number of dysfunctional segments at rest 9.6 (5.1) 8.8 (5.0) 0.1
Number of ischaemic segments 3.5 (2.2) 3.8 (2.1) 0.2
Arrhythmias and hypotension during the test 43 (7%) 12 (4%) 0.2
Reasons for termination of the stress test
85% of maximum heart rate 579 (90%) 250 (87%) 0.2
Maximum dose 36 (5%) 14 (5%) 0.8
Arrhythmias 12 (2%) 2 (1%) 0.3
Side effects 11 (2%) 1 (0.3%) 0.2
ST segment depression 5 (1%) 10 (3%) ,0.005
Angina 0 (0%) 11 (4%) ,0.0001
Data are mean (SD) or number (%).
Table 3 Medication at follow up of patients with and without angina during DSE
Baseline Follow up
Silent
ischaemia
(n = 643)
Symptomatic
ischaemia
(n = 288) p Value
Silent
ischaemia
(n = 643)
Symptomatic
ischaemia
(n = 288) p Value
b blockers 243 (38%) 115 (40%) 0.5 276 (43%) 202 (70%) ,0.001
Calcium channel
blockers
177 (27%) 99 (34%) 0.04 193 (30%) 89 (31%) 0.06
Nitrates 180 (28%) 115 (40%) 0.001 193 (30%) 69 (24%) ,0.006
Aspirin 302 (47%) 158 (55%) 0.005 334 (52%) 236 (82%) ,0.001
Statins 174 (27%) 92 (32%) 0.1 263 (41%) 245 (85%) ,0.001
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Significant changes were observed in medical treatment of
patients with and without angina during DSE. Patients with
silent myocardial ischaemia during DSE were less often
prescribed b blockers, aspirin, and statins than were patients
with symptomatic ischaemia. In addition, late revascularisa-
tion was less often performed in patients with asymptomatic
ischaemia during DSE. Moreover, in patients with multi-
vessel disease and symptomatic or silent ischaemia during
DSE, cardiac death occurred more often in medically treated
patients than in patients who underwent myocardial
revascularisation.
The worse long term prognosis of patients with asympto-
matic myocardial ischaemia may be associated with less
aggressive anti-ischaemic medical treatment and coronary
revascularisation. b Blockers have been unequivocally shown
in multiple studies to reduce angina and the incidence,
frequency, and extension of episodes of silent ischaemia.26–28
The combination of b blockers with other anti-ischaemic
medical treatment such as calcium channel antagonists has
also been found to reduce the incidence of myocardial
ischaemia more than either type of these medications
alone.29 30 Also, statins have been shown to decrease transient
myocardial ischaemia, probably due to improved endothelial
function.31 Furthermore, myocardial revascularisation was
previously shown in a prospective study to be associated with
decreased asymptomatic ischaemia and improved clinical
outcome compared with angina or ischaemia guided strat-
egy.32 In the present study, the decision to perform coronary
angiography was made on clinical grounds by the treating
cardiologist. The prescription rate of b blockers or calcium
antagonist was relatively low. It seems that in some patients
symptoms of angina instead of signs of ischaemia on DSE
were the reason to prescribe b blockers or calcium antago-
nists and to perform myocardial revascularisation.
Additionally, in this study absence of symptoms during
dobutamine stress induced ischaemia was often observed
(69%); this is in line with previous studies4 33 34 and is
physiologically explained by the ischaemic cascade, since
systolic dysfunction precedes the development of angina
pectoris.
Comparison with previous studies
There are only a few studies on the long term prognostic
implications of silent myocardial ischaemia during DSE. Bigi
and colleagues35 studied 407 survivors from a first uncom-
plicated myocardial infarction who had myocardial ischaemia
during DSE and were followed up for a 10 month period.
Cardiac death and non-fatal myocardial re-infarction
occurred, respectively, in six of 407 (1%) and 13 of 407
(3%) patients. No significant difference in spontaneous
event-free survival was observed among patients with silent
ischaemia. Bonou and colleagues33 studied 289 patients with
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Figure 1 Kaplan-Meier survival curves
(end point of cardiac death) for patients
with silent versus patients with
symptomatic ischaemia during
dobutamine stress echocardiography
(DSE).
Figure 2 Kaplan-Meier survival curves
(end point of cardiac death and non-
fatal myocardial infarction) for patients
with silent versus patients with
symptomatic ischaemia during DSE.
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advanced age undergoing DSE. During a 35 (13) month
follow up period, 15 (5%) cardiac deaths and 19 (7%) non-
fatal myocardial infarctions occurred. There was no signifi-
cant difference in prognosis between patients with silent
ischaemia and patients with symptomatic myocardial ischae-
mia. In the present study the cardiac event rate was higher
than in the previous studies; this may be related to the longer
and nearly complete (99.5%) follow up. Previous data from
224 patients who underwent dobutamine stress myocardial
perfusion imaging showed a similar outcome between
patients with silent ischaemia and patients with symptomatic
ischaemia.34 The different findings in that study may be
related to differences in sensitivity between myocardial
perfusion imaging and DSE, as well as a possible differences
in management of patients after a positive study by these two
techniques.
Some previous studies suggested a common pathway for
both the electrical and pain response to ischaemic stimulus.8
These studies showed that during exercise stress testing
patients with symptomatic ischaemia had a higher incidence
of ST segment changes.8 14 15 However, the extent of
ischaemia was comparable between patients with and
patients without symptomatic ischaemia during DSE. The
mechanism underlying the pathogenesis of silent or sympto-
matic ischaemia is complex and may include variations in
pain threshold, a central nervous system alteration, or a
particular biochemical pattern of inflammatory system
activation.36 37 The relation between angina and extent of
ischaemia is not clear. Several studies have assessed the
extent of ischaemia in the presence and in the absence of
symptomatic myocardial ischaemia during stress test with
contradictory results. Some investigators have reported a
greater extent and severity of ischaemia in symptomatic
patients than in those with silent myocardial ischaemia,11–16
whereas other studies reported no difference in the amount
of ischaemic myocardium between patients with and patients
without symptomatic myocardial ischaemia during exercise
or pharmacological stress testing.4–10 In the present study
there are no significant differences between dysfunctional
segments at rest and the number of ischaemic segments at
peak in patients with and without symptomatic myocardial
ischaemia. Moreover, the extent of ischaemia during DSE
was an independent predictor of cardiac death and myocar-
dial infarction, and the number of diseased vessels was
related to an increased rate of cardiac events, particularly in
patients with symptomatic ischaemia. This is in line with
previous studies that show the total amount of ischaemic
territory at risk is related more to the outcome than to the
presence of symptoms.3 18 19 38 39
Study limitations
Data on coronary angiography were not available for all
patients.
Conclusion
This study showed that patients with asymptomatic myo-
cardial ischaemia during DSE had a worse long term cardiac
event-free survival rate than did patients with symptomatic
myocardial ischaemia. Patients with asymptomatic ischaemia
should be treated with a complete medical therapy or
revascularisation as patients with symptomatic myocardial
ischaemia.
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he following electronic only articles are published in
conjunction with this issue of Heart.
Rheumatic involvement of all four cardiac valves
K Jai Shankar, P K Jaiswal, K M Cherian
Rheumatic involvement of all four heart valves is rare. A 35
year old woman presented with gradually progressive
exertional dyspnoea for the preceding 10 years. On evaluation
she was in atrial fibrillation with congestive heart failure.
Clinical examination found evidence of stenosis of the mitral
aortic and tricuspid valves with a history of rheumatic fever
in childhood. Transthoracic echocardiography showed the
involvement of all four cardiac valves. Few reports are
available in the literature describing rheumatic quadrivalvar
damage. Operator awareness of possible rheumatic involve-
ment of all four valves is essential for appropriate diagnosis.
(Heart 2005;91:e50) www.heartjnl.com/cgi/content/full/91/
6/e50
Fatal infection after rapamycin eluting coronary stent
implantation
F Alfonso, R Moreno, J Vergas
Septic complications after coronary stenting are extremely
rare. The occurrence of cardiac related sepsis after rapamycin
eluting stent deployment has not been previously reported.
The potential role of drug eluting stents in locally blunting
the innate response to bacterial agents is discussed.
(Heart 2005;91:e51) www.heartjnl.com/cgi/content/full/91/
6/e51
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